Swiss National Bank Grows Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Swiss National Bank raised its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 1.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 333,000 shares of the biotechnology company’s stock after buying an additional 4,700 shares during the period. Swiss National Bank’s holdings in Ironwood Pharmaceuticals were worth $4,126,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its position in shares of Ironwood Pharmaceuticals by 1,680.9% in the 3rd quarter. Victory Capital Management Inc. now owns 2,901,831 shares of the biotechnology company’s stock worth $30,063,000 after purchasing an additional 2,738,889 shares during the period. State Street Corp lifted its position in shares of Ironwood Pharmaceuticals by 31.2% in the 2nd quarter. State Street Corp now owns 10,886,805 shares of the biotechnology company’s stock worth $125,525,000 after purchasing an additional 2,589,738 shares during the period. BNP Paribas Arbitrage SNC lifted its position in shares of Ironwood Pharmaceuticals by 1,412.7% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 586,772 shares of the biotechnology company’s stock worth $6,079,000 after purchasing an additional 547,982 shares during the period. Renaissance Technologies LLC lifted its position in shares of Ironwood Pharmaceuticals by 16.6% in the 1st quarter. Renaissance Technologies LLC now owns 3,123,053 shares of the biotechnology company’s stock worth $39,288,000 after purchasing an additional 443,800 shares during the period. Finally, LSV Asset Management lifted its position in shares of Ironwood Pharmaceuticals by 5.8% in the 3rd quarter. LSV Asset Management now owns 7,914,220 shares of the biotechnology company’s stock worth $81,991,000 after purchasing an additional 435,063 shares during the period.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday.

Ironwood Pharmaceuticals Stock Up 2.4 %

NASDAQ:IRWD opened at $10.47 on Friday. Ironwood Pharmaceuticals, Inc. has a 52 week low of $9.73 and a 52 week high of $12.66. The firm has a 50 day moving average of $10.57 and a 200 day moving average of $11.26. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 10.37 and a beta of 0.95.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.01. Ironwood Pharmaceuticals had a net margin of 43.63% and a return on equity of 29.40%. The business had revenue of $104.06 million for the quarter, compared to analyst estimates of $100.60 million. During the same quarter in the prior year, the business posted $0.21 EPS. Ironwood Pharmaceuticals’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.05 EPS for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, COO Jason Rickard sold 16,746 shares of the company’s stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $11.41, for a total transaction of $191,071.86. Following the transaction, the chief operating officer now owns 350,077 shares in the company, valued at approximately $3,994,378.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Thomas A. Mccourt sold 21,148 shares of the stock in a transaction on Monday, May 8th. The shares were sold at an average price of $10.62, for a total value of $224,591.76. Following the sale, the chief executive officer now owns 820,916 shares in the company, valued at $8,718,127.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jason Rickard sold 16,746 shares of the stock in a transaction on Monday, February 27th. The stock was sold at an average price of $11.41, for a total transaction of $191,071.86. Following the completion of the sale, the chief operating officer now owns 350,077 shares in the company, valued at approximately $3,994,378.57. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,931 shares of company stock worth $1,790,377. 13.10% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

(Get Rating)

Ironwood Pharmaceuticals, Inc is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.